By: John Seaner, CMO, IPM.ai/Swoop
Last week, the New York Times published a story titled The Pandemic’s Hidden Victims: Sick or Dying, but Not From the Virus about the difficulty of obtaining care during the coronavirus pandemic, either because procedures have been canceled, medical supplies are unavailable or patients are too scared. The story covered life-saving treatments such as cancer treatments, organ transplants, and neurosurgery. And it started us thinking: If life-saving treatments are so difficult to access, then what about quality-of-life saving treatments?
We examined our data surrounding Botox for chronic migraine to uncover at the drug level, just how unavailable treatments have been made available to patients who require them. Chronic migraine patients are severely debilitated, suffering from 15 or more migraine days a month, and stress and anxiety worsen migraines. Botox is an in-office treatment, requiring patients to visit a doctor to obtain the therapy. But In these restricted times, are patients really making the trip to the doctor? The data demonstrates that stay-at-home orders have clearly affected chronic migraine patients’ access to relief:
- Botox treatments for migraine held steady through January, February, and early March.
- For the two-week period March 23 to April 5 of 2020, treatments declined by 58% compared to the two week period February 24th to March 8th. Those suffering from chronic migraines are following states’ stay-at-home orders and choosing to not visit their doctor for treatment.
- Declines were experienced across every state, with some showing declines of up to 88%.
- In the time period March 23 to April 5 there was a 45% increase in the total percentage of procedures performed by neurologists versus February 24th to March 8th, suggesting that the most severely affected are taking a potential risk and visiting medical facilities to receive treatment.
IPM.ai's system of insight empowers you to discover these trends in nearly real time.
About the Author
Chief Marketing Officer
John leads a team charged with amplifying our brand, communicating the organization’s business value, and earning the loyalty of our clients. He has a 30 year track record of driving innovation, operational improvement, profitable revenue growth and sustainable competitive advantage for technology companies ranging from early-stage startups to global billion-dollar public organizations. John previously served as Chief Marketing Officer of 1010data, provider of analytical intelligence, consumer insights and data sharing solutions; Chief Marketing Officer of Signals Analytics, an early pioneer in the emerging Decision Science as a Service space; and Vice President of Global Growth Marketing at Medidata Solutions, the world’s leading clinical development lifecycle platform utilized by over 1,500 life sciences companies. Throughout his career his teams have earned notable awards and accolades, most recently for pioneering new approaches in account-based marketing, including the use of digital ethnography to uncover the customer decision journey, the utilization of data science to optimize demand activation and the application of signals intelligence to enhance customer empathy.